Dick’s Sportings Goods hit with civil rights complaint over abortion benefits

Cracker Barrel announced last week that Julie Masino would be succeeded in her CEO and Director roles, effective August 10, by former Bloomin’ Brands CEO David Deno. Her failed tenure shows what happens when executives discard the most basic principles of business leadership. Although a company filing claims Masino was terminated without cause, this was an expected result given her leadership over Cracker Barrel’s disastrous rebranding efforts last year, which hurt its stock price by over $100 million. Masino was the second high-profile executive to leave the company since the rebranding effort, following DEI consultant Gilbert Dávila, who resigned after receiving only 42% of shareholder support at Cracker Barrel’s annual meeting last November. Too often, our corporate leadership class confuses social trends with long-term vision. Cracker Barrel now joins companies like Disney and Bud Light as a cautionary tale of what can happen when a company loses sight of its business fundamentals. For executives at other major American companies, the Cracker Barrel saga provides three strong lessons that, regrettably, still bear repeating: 1 Remain committed to your distinctives Read more 1 Remain committed to your distinctives A modernizing redesign stripped Uncle Herschel from the logo and cleared out the antiques, abandoning the brand’s core. 2 …

Press Release

Final NIH Report on Multi-Million Dollar Olson-Kennedy Study Shows Puberty Blockers Don’t Help Kids

Protecting Children

August 28, 2026

WASHINGTON, D.C. — The final report for the National Institutes of Health (NIH)-funded “Trans Youth Care” study led by Dr. Johanna Olson-Kennedy of Children’s Hospital Los Angeles was finally made public this month, after the government watchdog organization Oversight Project was forced to sue the agency for its release. The multi-year, multi-million-dollar observational study examining physiological and psychological effects of puberty blockers and sex-denying hormones on youth with gender dysphoria has concluded, and the final report was submitted January 6, 2026. This taxpayer-funded research was intended to evaluate longer-term impacts of these interventions. Its conclusions reinforce a growing body of evidence that puberty blockers lack reliable proof of benefit for children and carry long-known risks to bone density, fertility, sexual function, and development. “The mass medical experiments on children need to stop,” said Doug Napier, Executive Chairman and CEO of 1792 Exchange. “These findings align with the emerging consensus that there is no benefit, but significant risks of harm to children, including impacts on bone density, fertility, sexual function, and cognitive development.” “The Cass Review in the United Kingdom, the Finland study, and the U.S. Department of Health and Human Services’ own 2025 peer-reviewed report on pediatric gender dysphoria all underscore the serious concerns about the impacts of these experiments. And this study is yet another nail in the coffin for transgender ideology,” Napier continued. The data on puberty blockers for children continue to show no significant positive mental or emotional health gains. Earlier peer-reviewed and preprint analyses from the same “Trans Youth Care” cohort—tracking depression symptoms, emotional health, …